CART-19 Cells For MRD Positive CD19+ ALL

Fujian Medical University20 enrolled

Overview

CART-19 cells has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients who are refractory or at highest risk of relapse as defined by MRD+ status.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Acute Lymphoblastic Leukemia

Interventions

CART-19BIOLOGICAL

CART-19 cells treated

Eligibility

Sex: ALLMin age: 1 YearMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed written informed consent * Aged between 1-60 years * Patients with MRD positive CD19+ ALL * Cardiac: Left ventricular ejection fraction ≥ 50% * Adequate renal and hepatic function * Performance status: Karnofsky ≥ 70% Exclusion Criteria: * Pregnant or lactating females. * Any co-morbidity precluding the administration of CART-19 cells.

Locations (1)

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

RECRUITING

Outcomes

Primary Outcomes

Leukemia free survival

Time frame: 1 year

Secondary Outcomes

Adverse events that are related to treatment

Time frame: 1 year

Central Contacts

Jianda Hu, Prof.M.D.Ph.D

CONTACT

86-13959169016 drjiandahu@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.